Is hair transplantation feasible for a patient with linear morphea of the scalp that is inactive and has been disease‑free for at least 12–24 months after completing systemic therapy?

Hair Transplantation in Inactive Linear Morphea of the Scalp

Yes, hair transplantation is feasible and can be performed in patients with linear morphea (coup de sabre) of the scalp, but only after confirming the disease has been completely inactive for at least 12-24 months following completion of systemic therapy.

Critical Prerequisites Before Proceeding

The disease must be definitively inactive before any surgical intervention. Based on consensus guidelines for juvenile localized scleroderma management, methotrexate should be maintained for at least 12 months after achieving clinical remission before tapering 1. This means:

• Minimum waiting period: 12-24 months of documented disease inactivity after completing systemic therapy
• No signs of active inflammation: No erythema, warmth, or progression of the lesion
• Stable clinical assessment: Serial examinations confirming no disease activity

Evidence Supporting Hair Transplantation

The most relevant case report demonstrates that hair transplantation in coup de sabre (linear morphea) can achieve 86.7% graft survival rate at 12 months, with transplanted hairs growing 12-16 cm in length 2. This confirms that when the disease is truly inactive, hair transplantation is both safe and effective for cosmetic improvement.

However, a systematic review of hair transplantation in primary cicatricial alopecias shows important temporal considerations 3:

• Peak survival at 1 year: 82.7% graft survival
• Declining over time: 73.3% at 13-24 months, 58.4% at 25-36 months
• Disease reactivation risk: 4 patients developed reactivation after transplantation

Procedural Approach

Recommended technique: Follicular unit extraction (FUE) or follicular unit transplantation (FUT) using 2-3 hair follicular units from the occipital scalp 2, 4.

Pre-Transplant Verification Steps:

1. Scalp biopsy of the affected area to histologically confirm absence of active inflammation 5
2. Test session with limited grafts to assess survival before full transplantation 5
3. Clinical documentation of disease stability for 12-24 months minimum

Critical Caveats and Pitfalls

⚠️ Major risk: Performing transplantation while disease remains active can trigger reactivation and lead to graft failure 3. The inflammatory process in active morphea will destroy transplanted follicles.

⚠️ Long-term consideration: Graft survival diminishes over time in cicatricial alopecias, so patients should understand this is not necessarily a permanent solution 3.

⚠️ Patient selection: Only proceed in patients with end-stage, completely inactive disease who have completed the full course of systemic therapy (typically methotrexate for ≥12 months after remission) 1.

Monitoring Post-Transplantation

• Hair growth timeline: Visible growth begins at 4-5 months post-procedure 5
• Watch for reactivation: Monitor for any signs of disease recurrence (erythema, induration, progression)
• Long-term follow-up: Annual assessments to evaluate graft survival and disease status

The procedure is safe and effective when performed in truly inactive disease, but premature intervention risks both graft failure and disease reactivation.